



BeOne Medicines Achieves Climate Goal Ahead of Schedule and Sets New Targets, Reinforcing Commitment to Responsible Business and Sustainability

On October 21, 2025, BeOne Medicines Ltd. ("the company"), a leading global oncology company, announced the early achievement of its first quantitative climate goal, underscoring its commitment to environmental sustainability. Originally established in December 2023, the target aimed to reduce the carbon intensity of the company's Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 25% per unit of internally manufactured commercial product by 2026 from a 2021 baseline. This milestone was reached primarily through a strategic focus on energy conservation and efficiency improvements across operations and supplemented by the purchase of Energy Attribute Certificates.

In light of this accomplishment, BeOne is setting a new target: to reduce the carbon intensity of its Scope 1 and Scope 2 GHG emissions by 50% per unit of internally manufactured commercial product by 2030 from a 2024 baseline. The company plans to achieve this goal primarily through the expanded implementation of energy efficiency initiatives identified in several key facilities, which are projected to yield significant energy and cost savings as the organization continues to grow.

Additionally, the company is excited to announce its first quantitative Scope 3 goal, aiming for a 10% reduction in the carbon intensity of its Scope 3 GHG emissions per unit of internally manufactured commercial product by 2030 from a 2024 baseline. This target fulfills the commitment made in 2023 to set a quantitative Scope 3 emissions goal by 2025. BeOne plans to achieve this goal by engaging with strategic suppliers to improve primary data collection and climate capability building.

Together, these new targets reflect BeOne's dedication to environmental sustainability, operational resilience, and achieving long-term sustainable growth so it can continue to provide innovative therapies to more patients around the world. BeOne's Responsible Business and Sustainability (RB&S) strategy is built upon four key pillars: advancing global health, empowering our colleagues, innovating sustainably, and operating responsibly. To learn more about BeOne's RB&S strategy, achievements, and goals, please download a copy of our most recent report [here](#).

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's plans to achieve climate goals; the energy and cost savings that may result from BeOne's sustainability projects; and BeOne's dedication to environmental sustainability, operational resilience, and achieving long-term sustainable growth. Actual results may differ materially from those indicated

BeOne Medicines

55 Cambridge Pkwy, #700W
Cambridge, MA 02142
USA
[BeOneMedicines.com](https://www.BeOneMedicines.com)



in the forward-looking statements as a result of various important factors, including BeOne's ability to reduce its GHG emissions by the targeted amount or any amount at all; BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, and other services; and BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in announcement is as of the date of this announcement, and BeOne undertakes no duty to update such information unless required by law.

BeOne Medicines

55 Cambridge Pkwy, #700W
Cambridge, MA 02142
USA
BeOneMedicines.com